Search

This paper examines the role of forests in national climate policies of two countries very rich in woods: Russia and Canada. Canada has made efforts to reduce direct CO2 emissions in the national economy, intensify forestry, and increase greenhouse gas sequestration by forests. Russia focuses on the verification and recalculation of the carbon sequestration capacity of its forests. Analysis of the Russian and Canadian stationary models used to assess the carbon sequestration capacity of forests (ROBUL and CBM-CFS, respectively) shows that both the Canadian model and the Russian one derived from it reflect the stationary dynamics of forest stands, which inevitably results in a downward CO2 absorption trend. Even if the forest inventory is updated on a regular basis, the predictive components of such models are unable to take into account the variability of forest ecosystems and their adaptation to climate change. Models that describe global carbon fluxes (e.g., ones using FLUXNET and remote sensing data) provide significantly higher net carbon sequestration values and indicate a nondecreasing net carbon accumulation trend in forests. It is concluded that stationary and remote sensing models should be used together to assess net carbon sequestration and formulate key principles of national climate policies in countries rich in forests. [ABSTRACT FROM AUTHOR]

Prevention of hepatitis B virus (HBV) infection by vaccination can potentially eliminate HBV-related diseases. PreHevbrio™/PreHevbri® is a 3-antigen (S, preS1, preS2) HBV vaccine (3A-HBV) recently licensed for adults in the US, EU and Canada. This study evaluated antibody persistence in a subset of fully vaccinated and seroprotected (anti-HBs ≥ 10 mIU/mL) Finnish participants from the phase 3 trial (PROTECT) of 3A-HBV versus single-antigen HBV vaccine (1A-HBV). 465/528 eligible subjects were enrolled (3A-HBV: 244; 1A-HBV: 221). Baseline characteristics were balanced. After 2.5 years, more 3A-HBV subjects remained seroprotected (88.1 % [95 %CI: 84.1,92.2]) versus 1A-HBV (72.4 % [95 %CI: 66.6,78.3)], p < 0.0001) and had higher mean anti-HBs [1382.9 mIU/mL (95 %CI: 1013.8,1751.9) versus 252.6 mIU/mL (95 %CI: 127.5,377.6), p < 0.0001]. In multiple variable logistic regression analysis including age, vaccine, initial vaccine response, sex and BMI, only higher post dose 3 (Day 196) antibody titers significantly reduced the odds of losing seroprotection. [ABSTRACT FROM AUTHOR]